Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Akira Asai, Ohki Higuchi, Toshiyuki Kimura, Yoshihiro Kojima, Jun Kariya, Shinichi Oikawa
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence
10.1007/s001250100020 · 2001
Postprandial hyperglycemia and diabetes complications: is it time to treat?
10.2337/diabetes.54.1.1 · 2005
Prevention of type 2 diabetes by diet and lifestyle modification
10.1080/07315724.2005.10719479 · 2005
A systematic review of drug therapy to delay or prevent type 2 diabetes
10.2337/diacare.28.3.736 · 2005
Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
10.1016/j.diabet.2006.11.005 · 2007
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance
10.1016/s0140-6736(09)60222-1 · 2009
Effect of valsartan on the incidence of diabetes and cardiovascular events
10.1056/nejmoa1001121 · 2010
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
10.1016/s0140-6736(10)60746-5 · 2010
Effect of ramipril on the incidence of diabetes
10.1056/nejmoa065061 · 2006
Effect of nateglinide on the incidence of diabetes and cardiovascular events
10.1056/nejmoa1001122 · 2010
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
10.1016/s0140-6736(02)08905-5 · 2002
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
10.1001/jama.290.4.486 · 2003
Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.)
10.1021/jf010567e · 2001
Glycosidase inhibitors: update and perspectives on practical use
10.1093/glycob/cwg090 · 2003
Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats
10.3177/jnsv.50.161 · 2004
Sugar-mimicking glycosidase inhibitors: bioactivity and application
10.1007/s00018-008-8522-3 · 2009
Determination of 1-deoxynojirimycin in mulberry leaves using hydrophilic interaction chromatography with evaporative light scattering detection
10.1021/jf0306901 · 2004
Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans
10.1021/jf062680g · 2007
Report of the committee on the classification and diagnostic criteria of diabetes mellitus
2010
An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers
10.1093/ajcn/84.3.551 · 2006
Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects
10.2337/dc06-2120 · 2007
Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients
10.1007/bf00277486 · 1988
Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents
1990
Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol
10.1016/0026-0495(92)90168-a · 1992
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control
10.1016/s0140-6736(96)90672-8 · 1996
1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes
10.2337/dc06-1910 · 2006
α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis
10.2337/diacare.28.1.154 · 2005
Generic and product-specific health claim processes for functional foods across global jurisdictions
10.1093/jn/138.6.1228s · 2008
Health claim evidence requirements in Japan
10.1093/jn/138.6.1192s · 2008
No additional external references are available.